| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6241175 | Respiratory Medicine | 2016 | 6 Pages |
Abstract
No clinical benefits of low-doses azithromycin were present after one year of treatment in young CF patients. Selection for macrolide-resistant strains of bacteria occurred, which should lead to a reconsideration of the duration of azithromycin treatment in CF.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Clémentine Samson, Aline Tamalet, Hoang Vu Thien, Jessica Taytard, Caroline Perisson, Nadia Nathan, Annick Clement, Pierre-Yves Boelle, Harriet Corvol,